 At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label OL treatment will be enrolled into an open-label, 12 month extension period to evaluate the effect of RNF 44 mcg three times weekly treatment on the time to conversion to McDonald MS and time to conversion to CDMS. 